December 10, 2018

FDA Approves Biosimilar to Neulasta for Myelosuppressive Chemotherapy

By Kristen Coppock, MA, Editor
Published Online: Tuesday, Nov 06, 2018

“The list price of Neulasta has nearly tripled since approval in 2002 and now represents a $4 billion annual cost burden in the U.S.,” said Lanfear, in his statement.2 “Our in-depth understanding of the market will allow us to deliver significant value to patients, payors, and providers in the US, including 340B hospitals, small clinics and small hospitals.”

References

FDA. FDA approved Udenyca (pegfilgrastim-cbqv), biosimilar to Neulasta (pegfilgrastim)—Drug Information Update. FDA Division of Drug Information email. November 2, 2018. Accessed November 2, 2018.

U.S. FDA Approves UDENYCA™ (pegfilgrastim-cbqv) [news release]. Redwood City, CA; November 2, 2018: Coherus Biosciences. https://globenewswire.com/news-release/2018/11/02/1642328/0/en/U-S-FDA-Approves-UDENYCA-pegfilgrastim-cbqv.html. Accessed November 2, 2018.

About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us